Pharmaceutical / Drug Definition :
Inhibits secretion of gonadotropin, a luteinizing hormone (LH)-releasing hormone. Initially increases pituitary production of LH and follicle-stimulating hormone (FSH), which ultimately leads to deactivation of testicular and ovarian functions.
In the United States, Nafarelin Acetate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Nafarelin Acetate.
FDA Label Requirements and Exceptions
FDA Import Information
Nafarelin Acetate (Nafarelin Acetate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Nafarelin Acetate (Nafarelin Acetate Suppliers)
- Processors Nafarelin Acetate
- Repackers Nafarelin Acetate
- Relabelers Nafarelin Acetate
- Exporters Nafarelin Acetate
- Importers Nafarelin Acetate
For more information about Nafarelin Acetate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.